MedTrace Logo

Local vs Systemic Methotrexate in Management of Uterine Ectopic Pregnancy

NCT06554470 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-08-16

No results posted yet for this study

Summary

This study aims to compare local and systemic methotrexate in the management of uterine ectopic pregnancy regarding the duration of beta human chorionic gonadotropin (hCG) clearance and need for further management options.

Conditions

  • Local
  • Systemic
  • Methotrexate
  • Uterine Ectopic Pregnancy

Interventions

DRUG

Systemic Methotrexate

Patients will receive systemic methotrexate (intramuscular; 50 mg/m2 body weight).

DRUG

Local Methotrexate

Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-15
Primary Completion
2025-07-01
Completion
2025-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06554470 on ClinicalTrials.gov